A significant breakthrough in medical research has emerged as two recent studies published in the journal JAMA suggest that a new blood test could potentially detect advanced stages of
The research, led by teams at Boston University and Banner Health, focused on identifying a specific protein marker in blood samples taken from former football players while they were still alive. Following the deaths of these participants, researchers confirmed the presence of CTE through brain autopsies. By correlating the protein levels found in the blood with the autopsy results, the scientists were able to identify a consistent marker for the disease, specifically in its more advanced stages.
Advancements in CTE Diagnostics and Future Implications
Michael Alosco, co-director of clinical research at Boston University's CTE Center and co-senior author of the study, described the findings as a potential game changer for the field. While he expressed cautious optimism about the timeline for further development, he noted that the current findings are still in the discovery phase. The study examined 21 deceased players, including 12 professionals, seven collegiate athletes, and two high school players. Results indicated that the blood test successfully identified higher concentrations of the protein in those who had advanced-stage CTE, with the highest levels observed in individuals who also suffered from Alzheimer's disease.
A second study, published in JAMA by researchers from the Washington University School of Medicine in St. Louis, corroborated these findings by identifying the same blood biomarker in a separate group of 11 cases. Despite these promising results, the test is currently limited to detecting advanced CTE, which is characterized by symptoms such as memory loss, depression, and mood swings. Early stages of the disease, which are often asymptomatic, remain more difficult to identify.
The prospect of a diagnostic test has sparked conversation among athletes regarding the implications of knowing one's health status. Current and former NFL players have expressed mixed views on the utility of such testing. While some, like Washington Commanders quarterback Marcus Mariota, believe it could provide valuable insight for players at all levels, others, such as Minnesota Vikings safety Joshua Metellus, have suggested that knowing such information while still active in the league could fundamentally alter their approach to the game. Currently, there are no FDA-approved tests or treatments specifically for CTE, though the recent studies provide a foundation for future clinical trials and diagnostic development.